{"entity":{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","aka":["complete response","complete responses","complete remission","complete remissions","CR rate","CRi","CR/CRi","complete response rate","stringent complete response","sCR","partial response","partial responses","partial remission","PR rate","very good partial response","VGPR","stable disease","best response","best overall response","deep response","deep responses","complete response rates"],"tldr":"A complete response means every measurable trace of the cancer has disappeared on scans or in the marrow; a partial response means it has shrunk by at least 30% (RECIST) but is still there. Neither is the same as cure: microscopic disease can remain.","summary":"Solid tumour responses are defined by RECIST 1.1 (complete: all target lesions gone and nodes <10 mm; partial: ≥30% decrease in summed diameters; progressive: ≥20% increase or new lesions; stable: neither); lymphoma uses Lugano and PET; leukaemia uses marrow blast count and count recovery (CR, CRi for incomplete recovery); myeloma uses IMWG (stringent CR, VGPR, PR). Complete responses are the strongest single-arm signal and, when durable, drive accelerated approvals; the proportion of complete responders and the depth of response (MRD, ctDNA clearance) increasingly predict long-term outcome. In neoadjuvant settings pathological complete response is judged on the resected specimen, and clinical complete response guides organ preservation.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors"}],"tags":[],"related":["orr","recist","pcr","duration-of-response-term","umrd","progressive-disease"],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Trials"},"route":"/terms/complete-response-term/","neighbours":{"term":[{"id":"blasts","kind":"term","name":"Blasts (leukaemic blast cells)","route":"/terms/blasts/"},{"id":"deauville","kind":"term","name":"Deauville score and PET-adapted therapy","route":"/terms/deauville/"},{"id":"duration-of-response-term","kind":"term","name":"Duration of response (DoR) and disease control rate (DCR)","route":"/terms/duration-of-response-term/"},{"id":"induction-therapy","kind":"term","name":"Induction therapy","route":"/terms/induction-therapy/"},{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"},{"id":"progressive-disease","kind":"term","name":"Progressive disease and radiographic progression","route":"/terms/progressive-disease/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"},{"id":"umrd","kind":"term","name":"Undetectable MRD (uMRD / MRD-negative)","route":"/terms/umrd/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}]}}